Loading
A phase 1/2 trial of Iberdomide, Dexamethasone, Daratumumab in multiple myeloma, run by Celgene, active and no longer recruiting.
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma is a phase 1/2 interventional study registered as NCT02773030 by Celgene, with 466 participants enrolled, started 2016-10-14 and due to reach its primary completion in 2024-05-09. Interventions recorded: CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
466 enrolled.
95% CI 18.1 to 35.6; Figures from the ClinicalTrials.gov results section (first posted 2026-03-20), not from a publication · 95% CI 0.5 to 71.6
Sourcerange 0.1 to 395.0; Figures from the ClinicalTrials.gov results section (first posted 2026-03-20), not from a publication · range 0.1 to 247.0 · range 0.1 to 150.1 · range 2.1 to 269.1 · range 0.1 to 258.1 · range 4.1 to 246.3 · range 5.3 to 213.1 · range 8.3 to 46.7 · range 0.1 to 84.4 · range 0.1 to 127.9 · range 0.1 to 81.3
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) in Cohort D and Cohort H2primary | Cohort D: Treatment 1 | 107 | 26.2% | - | - | link |
| Cohort H2 | 5 | 20% | ||||
| Progression Free Survival | Cohort A: Total | 29 | 12.29 weeks | - | - | link |
| Cohort B: Total | 90 | 14.71 weeks | ||||
| Cohort D: Total | 107 | 12.14 weeks | ||||
| Cohort E: Total | 50 | 20.71 weeks | ||||
| Cohort F: Total | 29 | 15.14 weeks | ||||
| Cohort G: Total | 16 | 48.57 weeks | ||||
| Cohort H1 | 6 | 26.14 weeks | ||||
| Cohort H2 | 5 | 22.14 weeks | ||||
| Cohort I | 41 | 10.14 weeks | ||||
| Cohort J: Total | 18 | 107 weeks | ||||
| Cohort K | 75 | 57.14 weeks |
Shares Iberdomide, Cereblon E3 ligase modulators (CELMoDs), Daratumumab, Bortezomib.
Shares Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Daratumumab, Bortezomib.
Shares Iberdomide, Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Iberdomide, Carfilzomib, Daratumumab, Dexamethasone.
Shares Cereblon E3 ligase modulators (CELMoDs), Bortezomib, Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Carfilzomib, Daratumumab, Bortezomib, Dexamethasone.
Shares Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.